Genmab Reports 87% Response in EPCORE NHL-2 Lymphoma Trial
Genmab Reports 87% Response in EPCORE NHL-2 Lymphoma Trial

Genmab Reports 87% Response in EPCORE NHL-2 Lymphoma Trial

News summary

Genmab A/S is advancing multiple clinical trials targeting various cancers, including lymphoma, advanced solid tumors, metastatic solid tumors, and hematologic malignancies. Notably, their EPCORE NHL-2 trial combining Epcoritamab with R-ICE chemotherapy showed an 87% overall response rate and 65% complete response in patients with diffuse large B-cell lymphoma, highlighting a promising treatment for high-risk patients. Additionally, Genmab is investigating several experimental drugs such as GEN1286 for advanced solid tumors, GEN1042 in combination with radiotherapy and pembrolizumab for metastatic tumors (in partnership with BioNTech SE), and GEN1056 for patients lacking standard care options. The ongoing Phase 1/2 trial of GEN3014 (HexaBody®-CD38) in relapsed or refractory multiple myeloma aims to evaluate safety and efficacy compared to existing therapies like daratumumab. These studies are at various stages, with some actively recruiting and others progressing toward completion, which could significantly impact Genmab’s market position and investor confidence if positive results continue. Overall, Genmab’s broad oncology pipeline and collaborations underscore its potential to introduce novel cancer therapies and strengthen its competitive edge in the biotech sector.

Story Coverage
Bias Distribution
100% Left
Information Sources
daae85f0-2883-42fc-b085-888140adf30d
Left 100%
Coverage Details
Total News Sources
1
Left
1
Center
0
Right
0
Unrated
0
Last Updated
10 hours ago
Bias Distribution
100% Left
Related News
Daily Index

Negative

25Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News